David Nunns on behalf of the Gynae Guidelines Group Date:
|
|
- Chad Floyd
- 5 years ago
- Views:
Transcription
1 Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Borderline tumours of the ovary management and follow-up Author: Contact Name and Job Title Directorate & Speciality David Nunns Consultant Gynaecological Oncologist, NUH (on behalf of the gynae cancer MDT- clinical lead Jaf Abu) Family Health Date of submission Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Patients seen in gynaecology or oncology clinics Version 1 If this version supersedes another clinical guideline please be explicit about which guideline it replaces including version number. Statement of the evidence base of the guideline has the guideline been peer reviewed by colleagues? Evidence base: (1-6) 1 NICE Guidance, Royal College Guideline, SIGN (please state which source). 2a meta analysis of randomised controlled trials 2b at least one randomised controlled trial 3a at least one well-designed controlled study without 3b randomisation at least one other type of well-designed quasiexperimental study 4 well designed non-experimental descriptive studies (ie comparative / correlation and case studies) 5 expert committee reports or opinions and / or clinical experiences of respected authorities 6 recommended best practise based on the clinical experience of the guideline developer Consultation Process Ratified by: Target audience Review Date: (to be applied by the Integrated Governance Team) A review date of 5 years will be applied by the Trust. Directorates can choose to apply a shorter review date, however this must be managed through Directorate Governance processes. NA 5) British Gynae Cancer Society Guidance on Ovarian Cancer 0Ovarian%20Guidelines% pdf Senior medical staff David Nunns on behalf of the Gynae Guidelines Group Date: General gynaecologists and gynaeoncologists 12/01/2023 This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date.
2 Aims and purpose To guide the clinician (general gynaecologists and gynaeoncologists) on the management and follow-up of borderline tumours of the ovary. Background Patients with borderline tumours of the ovary account for 10% of all ovarian tumours. When correctly staged and malignancy excluded, the prognosis is excellent. The 5-year survival rate for such patients approaches 100%, however, the 10-year survival rate is 90-95%. Patients are commonly managed by general gynaecologists and a diagnosis made after resection on histology. All cases should be discussed at the gynaeoncology MDT as soon as possible and referred using the MDT referral form on the intranet. The desired outcome of management is complete staging, assessment of tumour risk, management of fertility concerns and surgical removal of all disease (the latter is linked to better survival compared to those patients with incomplete excision). 1
3 Algorithm for management and follow-of borderline tumours of the ovary (see text for peritoneal biopsy) Pathological types Borderline ovarian tumours are a subgroup of ovarian tumours that by definition have no evidence of stromal invasive histologically. Low risk patients usually behave in benign fashion and include the following; borderline endometrioid, clear cell, Brenner tumours and correctly diagnosed mucinous borderline tumours. o Mucinous borderline tumours typically present as large unilateral masses that are confined to the ovary. Non-ovarian mucinous tumours, including metastatic ovarian mucinous tumours associated with pseudomyxoma peritonei and metastatic mucinous carcinomas (Krukenberg tumours)(ronnett 2004). High risk patients include advanced stage disease, incompletely excised disease and some serous and sero-mucinous types. These are associated with a poorer prognosis. o Serous types with micropapillary and microacinar architecture have a greater association with extra-ovarian 2
4 disease and a higher incidence of recurrence and death from disease (Seidman 2000). They can be associated with microinvasion (small areas of invasion less than 5mm). Microinvasion is seen more commonly in pregnant patients but the presence of microinvasion does not alter the outcome (Mooney 1997). Women with stage I disease have the same outcome as the general population, irrespective of microinvasion (Bell 2001) o Serous borderline tumours can also be associated with peritoneal lesions that are termed implants (which influences final stage) Non invasive implants are when the implants are confined to peritoneal/ mesothelial lined surfaces and lack invasion of underlying tissue; these patients have a good prognosis. Invasive implants may occur and these patients need careful management and some patients have a poor prognosis. They should be reclassified as low grade ovarian cancers under the new FIGO classification of Preoperative management Currently there is no reliable means of preoperative detection of borderline tumours clinically and on imaging. Please refer to the NUH guidance Assessment, referral and initial management of ultrasound detected ovarian cysts for NUH gynaecology teams for further information on complex ovarian cysts. Intraoperative management There may be an intraoperative suspicion of a borderline tumour that was not suspected preoperatively (eg external papillary-like tumour on the surface of the ovary, ascites, evidence of peritoneal and omentum nodularity see appendix 1). If the patient has consented to oophorectomy then, o Take a sample of the ascites or carry out peritoneal washings prior to resection o Observe the other ovary for abnormality. In premenopausal women when there is external papillary-like tumour on the surface of the ovary it is not unreasonable to biopsy this disease. In a post-menopausal patient removal of the remaining ovary may be considered. There will be consent 3
5 issues in this situation and a judgement will have to made by the lead surgeon. o Take a generous omental biopsy if the omentum looks normal (eg at least 3x3cm). The omentum looks abnormal then, if possible, either remove the majority of the omentum with the disease, or take a generous omental biopsy which includes the disease. o Inspect all the peritoneal surfaces and take single or multiple biopsies if necessary (see below). Inspect the appendix. o If total resection of the disease is not possible (eg bowel involvement, fixed disease) then distinguishing between cancer and borderline disease is difficult. Please consider calling a colleague in gynaeoncology for advice or performing an oophorectomy and omentectomy if safe and discuss results with a member of the gynaeoncology team postoperatively. o Please document clearly intraoperative findings and take photographs if possible (so to plan any subsequent surgery). o Consider appendicectomy for apparent mucinous tumours (the ovarian tumour may be a metastasis). o Pelvic and para-aortic lymph node sampling to stage cases is not recommended in the absence of bulky lymph nodes. Peritoneal Biopsies What are peritoneal biopsies? o These are small superficial piece(s) of peritoneal tissue usually less than 1cm in size. Why are they beneficial? o knowledge of the histology assists in the diagnosis and staging of intra-abdominal gynaecological malignancy (eg borderline and malignant tumours) When should they be taken? At the primary operation (all gynaecologists). If intraoperatively a borderline/malignant tumour is suspected (eg exophytic growth on the ovary see clinical pictures in the appendix) then the gynaecologist is advised to look at all the peritoneal surfaces and biopsy any suspicious area of disease. Taking the biopsy is determined by the confidence of the gynaecologist as some site (eg pelvic sidewall) may be more difficult than others. Please document all findings in the notes. Restaging procedures (usually the gynaeoncologist). Peritoneal biopsies should be taken when there is a known diagnosis of borderline disease to support disease staging (see below) How should they be taken? 4
6 Follow-up Peritoneal biopsies are usually taken from the pelvis, paracolic gutters, anterior abdominal wall and subdiaphragmatic surfaces. It is important to avoid excessive diathermy artefact and suturing the defect is not usually necessary. Patients should be followed up as per the algorithm above. Patients who have been fully staged and who have had both ovaries removed can be followed up clinically. The three year follow-up period is likely to detect most (but not all) recurrences. Many patients are diagnosed post-operatively so additional surgery and /or follow-up may need to be considered based on fertility requirements, tumour type and fitness. The risk of recurrence in low-risk stage 1 disease is not clear but as a general guide o following oophorectomy the risk of a recurrent borderline tumour in the remaining ovary is 10%. o following cystectomy the risk of a recurrent borderline tumour in the same ovary approximately 30% (so completion oophorectomy is advised even if fertility is required) (Trillsch 2014) o Longer-term, the risk of malignant transformation is low overall (~2%), but is found in 30% of those with relapsed disease, although was much less frequent in women under 40 years of age at original diagnosis, compared to those aged over 40 years (12.0% versus 66.7%, P < 0.001) (Trillsch 2014). There is no evidence that routine follow-up is of value in detection of recurrence and cancer Ultrasound follow-up (preferably transvaginal route) should be reserved for those women who retain an ovary. Completion oophorectomy when the patient s family is complete can be considered but the evidence of benefit is not clear. Removal of the uterus is not considered an essential part of the primary treatment, but may be relevant if the patients will have hormone replacement therapy post-operatively or needed to excise all visible disease. There is unclear value in the routine CA125 based follow up. This needs discussion with the gynae cancer team (du Bois 2013) Relapse of borderline disease should be mainly treated surgically, if disease seems operable, since response to chemotherapy is poor. 5
7 There is no evidence-based indication for cytotoxic chemotherapy (Faluyi 2010) Appendix 1 clinical intraoperative images of abnormal ovaries consistent with borderline tumour of the ovary. External papillary-like tumour on the surface of the ovary (carry out small biopsy of external surface tumour approx. 5mm size) Peritoneal nodularity (take pictures and multiple peritoneal biopsies using biopsy forceps or diathermy scissors) 6
8 Peritoneal nodularity (take pictures and multiple peritoneal biopsies using biopsy forceps or diathermy scissors) Appendix 1 patient information sheet General advice on counselling patients on borderline tumours o It is not a cancer o Chemotherapy is rarely given o The prognosis is excellent o Referral to the gynae cancer team may be needed for ongoing management and follow-up 7
9 Use the patient information sheet developed by the charity Ovacome ( content/uploads/2016/02/fact-sheet-10-borderline- TUMOURS-2016.pdf) References Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol Apr;25(4): PubMed PMID: British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer May;49(8): PubMed PMID: Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev Sep 08(9):CD PubMed PMID: Pubmed Central PMCID: PMC Mooney J, Silva E, Tornos C, Gershenson D. Unusual features of serous neoplasms of low malignant potential during pregnancy. Gynecologic oncology Apr;65(1):30-5. PubMed PMID: Ronnett BM, Kajdacsy-Balla A, Gilks CB, Merino MJ, Silva E, Werness BA, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol Aug;35(8): PubMed PMID: Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol May;31(5): PubMed PMID: Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, et al. Agedependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol Jul;25(7): PubMed PMID:
Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran
ORIGINAL ARTICLE Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran Katayoun Ziari, Ebrahim Soleymani, and
More informationFertility Preservation Is Safe for Serous Borderline Ovarian Tumors
ORIGINAL STUDY Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors Eveline Vancraeynest, MD,* Philippe Moerman, MD, PhD,Þ Karin Leunen, MD, PhD,* Frédéric Amant, MD, PhD,* Patrick Neven,
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationLow-grade serous neoplasia. Robert A. Soslow, MD
Low-grade serous neoplasia Robert A. Soslow, MD soslowr@mskcc.org Outline Orientation Ovarian tumor overview Non serous borderline tumors Serous borderline tumors Clinical summary Morphologic description
More informationOvarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center
Ovarian Tumors Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center Case 13yo female with abdominal pain Ultrasound shows huge ovarian mass Surgeon
More informationThe impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients ( 40 years old) with borderline ovarian tumors
Fang et al. BMC Cancer (2018) 18:1147 https://doi.org/10.1186/s12885-018-4932-2 RESEARCH ARTICLE Open Access The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients
More informationClinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122
Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBibliography. Serous Tumors of the Ovary. Nomenclature
Bibliography Serous Tumors of the Ovary Nomenclature 1. Allison KH, Swisher EM, Kerkering KM, et al. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationBorderline tumors. Borderline tumors. Serous borderline tumor are NOT benign. Low grade serous carcinoma: pathogenesis. Serous carcinoma: pathogenesis
Serous borderline tumor are NOT benign Robert A. Soslow, MD Memorial Sloan-Kettering Cancer Center soslowr@mskcc.org Borderline tumors Serous BTs and seromucinous BTs are both histopathologically borderline
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More informationArticle begins on next page
Pseudopapillary Granulosa Cell Tumor: A Case of This Rare Subtype Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/50622/story/]
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationA Survay on Appendiceal Involvement in Ovarian Mucinous Tumors
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.33 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 199 203 ISSN 2330-4456 A Survay
More informationBorderline Ovarian Tumours. Andreas Obermair Brisbane
Borderline Ovarian Tumours Andreas Obermair Brisbane Definition First described in 1929 Cellular features of malignancy Cellular atypia Mitotic activity No stromal invasion An entity per se??? (or precursor
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationA Serous Borderline Tumor of the Fallopian Tube Detected Incidentally
A Serous Borderline Tumor of the Fallopian Tube Detected Incidentally Imrana Tanvir, Ghania Ali, Haseeb Ahmed Khan and Ahmed Nasir Hanifi* Dept. of Histopathology, FMH College of Medicine & Dentistry,
More informationSurgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT)
Trillsch et al. Journal of Ovarian Research 2013, 6:48 RESEARCH Open Access Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT) Fabian Trillsch 1, Jan
More informationOriginal contribution
Human Pathology (2012) 43, 747 752 www.elsevier.com/locate/humpath Original contribution The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationSpecialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management
More informationOvarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer
Issue date: April 2011 Ovarian cancer The recognition and initial management of ovarian cancer Developed by the National Collaborating Centre for Cancer About this booklet This is aquick reference guide
More informationPlease complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Author: Contact Name and Job Title Directorate & Speciality Assessment, referral and initial management of ultrasound
More informationGestione dei tumori borderline iniziali e avanzati nelle donne in età fertile
Gestione dei tumori borderline iniziali e avanzati nelle donne in età fertile Pierandrea De Iaco pierandrea.deiaco@aosp.bo.it SSD ONCOLOGIA GINECOLOGICA AOU SANT ORSOLA-MALPIGHI BOLOGNA Borderline ovarian
More informationCase # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor
Case # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor Robert J Kurman, M.D. Johns Hopkins University School of Medicine Case History A 53 year
More informationThis policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.
Medical Coverage Policy Multimarker Serum Testing Related to Ovarian Cancer EFFECTIVE DATE: 10 01 2015 POLICY LAST UPDATED: 04 17 2018 OVERVIEW This policy documents the coverage determination for Multimarker
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationGeneral history. Basic Data : Age :62y/o Date of admitted: Married status : Married
General history Basic Data : Age :62y/o Date of admitted:940510 Married status : Married General history Chief Complain : bilateral ovarian cyst incidentally being found out during pap smear. Present Illness
More informationCA125 in the diagnosis of ovarian cancer: the art in medicine
CA125 in the diagnosis of ovarian cancer: the art in medicine Dr Marcia Hall Consultant Medical Oncology Mount Vernon Cancer Centre Hillingdon Hospital Wexham Park Hospital Epidemiology Ovarian cancer
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationEpithelial ovarian cancer
Scottish Intercollegiate Guidelines Net work 75 Epithelial ovarian cancer A na tion al clinical guideline 1 Introduction 1 2 Screening and the role of prophylactic oophorectomy 3 3 Diagnosis 6 4 Surgical
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationSerous Borderline Tumors of the Ovary: Implants, Manifestations, Biology & New Insights in Progression
Serous Borderline Tumors of the Ovary: Implants, Manifestations, Biology & New Insights in Progression Stanley J. Robboy, MD Professor of Pathology Professor of Obstetrics & Gynecology Vice Chairman for
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationLCA Gynaecological Cancer Clinical Guidelines
LCA Gynaecological Cancer Clinical Guidelines July 2014 LCA GYNAECOLOGICAL CANCER CLINICAL GUIDELINES Contents Introduction... 5 Executive summary... 6 1 The Structure of Gynaecology Oncology Services...
More informationLow-Grade Serous Ovarian Tumors Debra A. Bell, MD Mayo Clinic and Mayo Medical School Rochester, MN
1 Low-Grade Serous Ovarian Tumors Debra A. Bell, MD Mayo Clinic and Mayo Medical School Rochester, MN It is very appropriate to discuss low-grade ovarian serous neoplasms in a symposium in honor of Dr.
More informationRole of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters
Naz et al. World Journal of Surgical Oncology (2015) 13:315 DOI 10.1186/s12957-015-0732-1 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Role of peritoneal washing in ovarian malignancies: correlation
More informationبسم هللا الرحمن الرحيم. Prof soha Talaat
بسم هللا الرحمن الرحيم Ovarian tumors The leading indication for gynecologic surgery. Preoperative characterization of complex solid and cystic adnexal masses is crucial for informing patients about possible
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationOvarian Cancer What you need to know
Ovarian Cancer What you need to know www.ovarian.org.uk Contents Your body and your ovaries What is ovarian cancer? Your body and your ovaries 3 What is ovarian cancer? 3 Not one disease, but many 4 The
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationFast Facts: Ovarian Cancer
Fast Facts Fast Facts: Ovarian Cancer Christina Fotopoulou MD PhD Consultant Gynaecological Oncologist Queen Charlotte s and Chelsea Hospital London, UK Thomas J Herzog MD Professor of Obstetrics and Gynecology
More informationBasic Data. Birthday: Gender:Female Admission date:
Basic Data Birthday:1951-07-02 Gender:Female Admission date:2004-06-28 Chief Complaint A protruding mass over RLQ abdomen for many years. Present Illness & Past History Pseudomyxoma peritonei s/p laparotomy
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationORIGINAL ARTICLE CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL
CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL Madhuri Kulkarni 1, Ambarish Bhandiwad 2, Sunila R 3, Sumangala 4. 1. Professor, Department
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationCase 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst
Gynaecology Case Presentation Organ Imaging 2016 University of Toronto Sarah Johnson 39 year old female Clinical history: Assess right ovarian cyst Clinically diagnosed endometriosis Started fertility
More informationMucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology
Mucinous Tumors of the Ovary Beirut, Lebanon Anaís Malpica, M.D. Professor Department of Pathology Primary Mucinous Tumors of the Ovary Cystadenoma Borderline (Tumor of Low Malignant Potential/Atypical
More informationGynaecological Oncology Unit Lead
Learning Outcomes: Gynaecological Oncology Unit Lead To develop knowledge and skills required by an individual to undertake the role as the Gynaecologial Oncology Unit Lead. Gynaecological Cancers Knowledge
More informationOvarian carcinoma classification. Robert A. Soslow, MD
Ovarian carcinoma classification Robert A. Soslow, MD soslowr@mskcc.org WHO classification Serous Mucinous Endometrioid Clear cell Transitional Squamous Mixed epithelial Undifferentiated Introduction Rationale
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationStage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
Original Investigation 33 Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Gökhan Boyraz, Derman Başaran, Mehmet
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationAppendix cancer mimicking ovarian cancer
Int J Gynecol Cancer 2002, 12, 768 772 CORRESPONDENCE AND BRIEF REPORTS Appendix cancer mimicking ovarian cancer P. A. GEHRIG *, J. F. BOGGESS*, D. W. OLLILA, P. A. GROBEN & L. VAN LE* *Division of Gynecologic
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationHereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families
Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationOvarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)
Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care
More informationOne of the commonest gynecological cancers,especially in white Americans.
Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in
More informationTUMOR AND TUMOR-LIKE CONDITIONS OF THE PERITONEUM AND OMENTUM/MESENTERY 40 th. Annual Meeting SCBTMR September 9-13, 2017, Nashville, Tennessee
TUMOR AND TUMOR-LIKE CONDITIONS OF THE PERITONEUM AND OMENTUM/MESENTERY 40 th. Annual Meeting SCBTMR September 9-13, 2017, Nashville, Tennessee Isaac R Francis University of Michigan Department of Radiology
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationMucinous Adenocarcinoma Involving the Ovary: Comparative Evaluation of the Classification Algorithms using Tumor Size and Laterality
J Korean Med Sci 2010; 25: 220-5 ISSN 1011-8934 DOI: 10.3346/jkms.2010.25.2.220 Mucinous Adenocarcinoma Involving the Ovary: Comparative Evaluation of the Classification Algorithms using Tumor Size and
More informationA Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Gynecologic Oncology A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants INES VASCONCELOS,JESSICA OLSCHEWSKI,IOANA BRAICU,JALID
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationCharacterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010
Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010 Evan S. Siegelman MD University of Pennsylvania Medical Center Adnexal Masses: Pearls
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More informationEpithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?
Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Ann E. Smith Sehdev, MD Director, Center for Gynecologic Pathology Cascade Pathology, Portland, Oregon Ann E. Smith Sehdev has no
More informationOvarian Cancer Quality Performance Indicators (QPI) Comparative Report
SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report Dr Cameron Martin, SCAN Lead Ovarian Cancer Clinician Dr Scott
More informationShared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1
Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas
More informationManagement of Ovarian Cancer
Management of Ovarian Cancer Version FINAL Release date 15/07/2011 Authors Mr. Kerryn Lutchman Singh Dr Gianfilippo Bertelli Dr Rachel Jones Review date 15/7/2013 1 2 Table of Contents Foreword... 4 Introduction...
More informationClinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors
REPRODUCTIVE SURGERY Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors Yoav Yinon, M.D., Mario E. Beiner, M.D., Walter
More informationSEROUS TUMORS. Dr. Jaime Prat. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona
SEROUS TUMORS Dr. Jaime Prat Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Serous Borderline Tumors (SBTs) Somatic genetics Clonality studies have attempted to dilucidate whether
More informationNAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationQ: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?
Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the
More informationUnexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine
Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy
More informationISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae
ISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae Learning objectives At the end of the lecture series you will be able to: Compare the differences between typical
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationRecurrence of sex cord tumor with annular tubules in young patient with Peutz-Jeghers syndrome
Slimane et al. 74 CASE REPORT PEER REVIEWED OPEN ACCESS Recurrence of sex cord tumor with annular tubules in young patient with Peutz-Jeghers syndrome Meher Slimane, Selma Gadria, Manel Hadidane, Houyem
More informationSection 1. Biology of gynaecological cancers: our current understanding
Section 1 Biology of gynaecological cancers: our current understanding Chapter 1 Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W Glenn McCluggage 1 Introduction In most
More informationNATIONAL CLINICAL GUIDELINE INVESTIGATION AND MANAGEMENT OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN
NATIONAL CLINICAL GUIDELINE INVESTIGATION AND MANAGEMENT OF OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical
More informationOvarian serous tumors of low malignant potential
ORIGINAL ARTICLE Lymph Node Involvement in Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors) Pathology, Prognosis, and Proposed Classification Jesse K. McKenney, MD, Bonnie L. Balzer,
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationCancer of Unknown Primary (CUP) Protocol
1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date
More informationPredictive value of CA 125 and CA 72-4 in ovarian borderline tumors
Article in press - uncorrected proof Clin Chem Lab Med 2009;47(5):537 542 2009 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2009.134 2009/623 Predictive value of CA 125 and CA 72-4 in ovarian
More informationInformation for health professionals - pseudomyxoma peritonei
Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationOvarian Cancer Audit Comparative Annual Report 01/01/ /12/2009
SE Scotland Cancer Network SCAN AUDIT Ovarian Cancer Audit Comparative Annual Report 01/01/2009 31/12/2009 S E Scotland Cancer Network (SCAN) (Excluding Dumfries and Galloway) NHS Borders NHS Fife NHS
More informationThe Origin of Pelvic Low-Grade Serous Proliferative Lesions
The Origin of Pelvic Low-Grade Serous Proliferative Lesions Ovarian Atypical Proliferative (Borderline) Serous Tumors, Noninvasive Implants and Endosalpingiosis Robert J. Kurman, M.D. Kurman RJ, Vang R,
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More information